Literature DB >> 17351897

Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches.

Peter Lane1.   

Abstract

This study compares two methods for handling missing data in longitudinal trials: one using the last-observation-carried-forward (LOCF) method and one based on a multivariate or mixed model for repeated measurements (MMRM). Using data sets simulated to match six actual trials, I imposed several drop-out mechanisms, and compared the methods in terms of bias in the treatment difference and power of the treatment comparison. With equal drop-out in Active and Placebo arms, LOCF generally underestimated the treatment effect; but with unequal drop-out, bias could be much larger and in either direction. In contrast, bias with the MMRM method was much smaller; and whereas MMRM rarely caused a difference in power of greater than 20%, LOCF caused a difference in power of greater than 20% in nearly half the simulations. Use of the LOCF method is therefore likely to misrepresent the results of a trial seriously, and so is not a good choice for primary analysis. In contrast, the MMRM method is unlikely to result in serious misinterpretation, unless the drop-out mechanism is missing not at random (MNAR) and there is substantially unequal drop-out. Moreover, MMRM is clearly more reliable and better grounded statistically. Neither method is capable of dealing on its own with trials involving MNAR drop-out mechanisms, for which sensitivity analysis is needed using more complex methods. Copyright 2007 John Wiley & Sons, Ltd.

Mesh:

Year:  2008        PMID: 17351897     DOI: 10.1002/pst.267

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  66 in total

1.  Randomized clinical trial comparing family-based treatment with adolescent-focused individual therapy for adolescents with anorexia nervosa.

Authors:  James Lock; Daniel Le Grange; W Stewart Agras; Ann Moye; Susan W Bryson; Booil Jo
Journal:  Arch Gen Psychiatry       Date:  2010-10

2.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

3.  Missing data in alcohol clinical trials: a comparison of methods.

Authors:  Kevin A Hallgren; Katie Witkiewitz
Journal:  Alcohol Clin Exp Res       Date:  2013-07-24       Impact factor: 3.455

4.  Mothers with depression, anxiety or eating disorders: outcomes on their children and the role of paternal psychological profiles.

Authors:  Silvia Cimino; Luca Cerniglia; Marinella Paciello
Journal:  Child Psychiatry Hum Dev       Date:  2015-04

5.  A randomized clinical trial of a telephone depression intervention to reduce employee presenteeism and absenteeism.

Authors:  Debra Lerner; David A Adler; William H Rogers; Hong Chang; Annabel Greenhill; Elina Cymerman; Francisca Azocar
Journal:  Psychiatr Serv       Date:  2015-03-01       Impact factor: 3.084

6.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

7.  The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.

Authors:  Raye Z Litten; I-Jen P Castle; Daniel Falk; Megan Ryan; Joanne Fertig; Chiung M Chen; Hsiao-ye Yi
Journal:  Alcohol Clin Exp Res       Date:  2013-07-24       Impact factor: 3.455

8.  Pharmacogenetics of antidepressive treatment.

Authors:  Astrid Zobel; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-01-03       Impact factor: 5.270

9.  Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

10.  Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.

Authors:  Hans-Jürgen Möller; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.